Atlas Trials

A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer

Clinical trial NCT03632941 · TERMINATED

Trial details

NCT number
NCT03632941
Sponsor
Herbert Lyerly
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Breast CancerHER2+ Breast Cancer
Start date
2019-03-01
Primary completion
2023-09-03
Enrollment
8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.